Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
NCT06945406 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 16, 2025
- Completion date
- March 31, 2027
- Enrollment
- 124 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.